Physician profile
Abigail S Smith
NPI 1205043445
$1,800.70
in general payments reported to CMS, 2019-2025
35 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $134 · 2022: $396 · 2023: $294 · 2024: $217 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $255.03 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $168.39 | 2019-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $150.96 | 2019-2025 | Injectafer |
| Organon LLC | $93.59 | 2023-2025 | Nexplanon |
| Amgen INC. | $90.04 | 2019-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $89.40 | 2020-2025 | |
| Novo Nordisk INC | $87.03 | 2019-2023 | Wegovy |
| Pfizer INC. | $80.10 | 2019-2024 | |
| Lupin INC. | $72.69 | 2019 | |
| Therapeuticsmd, INC. | $68.68 | 2019-2022 | |
| Exeltis, USA INC. | $68.48 | 2022-2025 | Slynd |
| Agile Therapeutics, INC. | $65.23 | 2022-2024 | Twirla |
| Duchesnay USA Incorporated | $45.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.28 | 2019-2020 | |
| Abbott Laboratories | $36.46 | 2024 | Diamondback Peripheral, Absolute Pro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $35.79 | 2022-2023 | Ova1 |
| Meditrina | $28.70 | 2023 | |
| Merck Sharp & Dohme LLC | $27.69 | 2019-2022 | |
| Masimo Corporation | $26.50 | 2022 | |
| Millicent US INC | $25.54 | 2019-2020 | |
| Shield Therapeutics INC | $23.58 | 2022 | |
| Amag Pharmaceuticals, INC. | $23.31 | 2019 | |
| Solventum Corporation | $22.75 | 2025 | V.A.C. Dermatac, Activ.A.C. |
| Allergan, INC. | $21.73 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.19 | 2022 | |
| Urovant Sciences INC | $17.87 | 2022 | |
| Sumitomo Pharma America, INC. | $17.26 | 2023 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $14.37 | 2022 | |
| Scynexis, INC. | $12.99 | 2022 | |
| Gilead Sciences, INC. | $12.85 | 2019 | |
| Evofem Biosciences, INC. | $12.51 | 2022 | |
| Coloplast Corp | $12.48 | 2019 | |
| Avion Pharmaceuticals | $11.74 | 2019 | |
| Hologic Sales and Service, LLC | $11.43 | 2019 | |
| Currax Pharmaceuticals LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.